logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 1
  • Knutsen, Lars Jacob Stray
    Research Director born in January 1955
    Individual (2 offsprings)
    Officer
    icon of calendar 2019-07-26 ~ now
    OF - Director → CIF 0
    Mr Lars Jacob Stray Knutsen
    Born in January 1955
    Individual (2 offsprings)
    Person with significant control
    icon of calendar 2019-07-26 ~ now
    PE - Right to appoint or remove directorsCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
    PE - Ownership of shares – 75% or moreCIF 0
parent relation
Company in focus

DISCOVERY PHARMA CONSULTING (UK) LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Property, Plant & Equipment
419 GBP2024-12-31
811 GBP2023-12-31
Debtors
6,486 GBP2024-12-31
12,597 GBP2023-12-31
Cash at bank and in hand
64,685 GBP2024-12-31
57,355 GBP2023-12-31
Current Assets
71,171 GBP2024-12-31
69,952 GBP2023-12-31
Net Current Assets/Liabilities
61,652 GBP2024-12-31
67,222 GBP2023-12-31
Equity
Called up share capital
100 GBP2024-12-31
100 GBP2023-12-31
Retained earnings (accumulated losses)
61,971 GBP2024-12-31
67,933 GBP2023-12-31
Equity
62,071 GBP2024-12-31
68,033 GBP2023-12-31
Average Number of Employees
22024-01-01 ~ 2024-12-31
22023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Gross Cost
Plant and equipment
1,567 GBP2024-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
1,148 GBP2024-12-31
756 GBP2024-01-01
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Plant and equipment
392 GBP2024-01-01 ~ 2024-12-31
Property, Plant & Equipment
Plant and equipment
419 GBP2024-12-31
811 GBP2023-12-31
Trade Debtors/Trade Receivables
5,326 GBP2024-12-31
12,597 GBP2023-12-31
Other Debtors
1,160 GBP2024-12-31
Taxation/Social Security Payable
Amounts falling due within one year
1,283 GBP2023-12-31
Other Creditors
Amounts falling due within one year
9,519 GBP2024-12-31
1,447 GBP2023-12-31

  • DISCOVERY PHARMA CONSULTING (UK) LTD
    Info
    Registered number 12125358
    icon of addressSt John's Innovation Centre, Cowley Road, Cambridge CB4 0WS
    Private Limited Company incorporated on 2019-07-26 (6 years 2 months). The company status is Active.
    The last date of confirmation statement was made at 2024-08-22
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022-2025 Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 26 August 2025 and licensed under the Open Government Licence v3.0.